

ASX Announcement

19 May 2026

BCAL early detection cancer referral forms now accessible to 97% of Australian GPs, Digital strategy and telemedicine platform launch through Earlydetection.com.au

Highlights

- BCAL establishes national referral infrastructure to support access to its early cancer detection test portfolio and scale commercial distribution
- Clinical referral forms live on Best Practice and Medical Director, covering 97% of Australian GPs
- Integration on Genie (Magentus), Australia's leading specialist practice management platform
- EarlyDetection.com.au telehealth service (with Medmate), launched 12 May – Dr Martin A. Devitt to lead
- Multi-Cancer Early Detection test coming June 2026; pancreatic addressable market >A\$250M p.a.
- Centre for Early Detection clinic for high-risk patients opening in Sydney CBD
- EarlyDetection Platform registered in New Zealand, UK, USA, India and additional international markets

BCAL Diagnostics Limited (ASX: BDX), an Australian healthcare company pioneering diagnostics for early detection of cancer, has materially expanded access to its early cancer detection tests by embedding referral pathways into major GP and specialist clinical software systems, while also launching a telehealth channel and establishing a Sydney clinic to support patient access.

Clinical referral forms for BCAL's early detection tests are now live on Best Practice and Medical Director, two leading GP clinical software platforms that together cover approximately 97% of Australian general practitioners. This provides BCAL with a significant national access pathway into primary care, where patient risk assessment and referral decisions are commonly made.

This referral infrastructure complements BCAL's existing laboratory and distribution arrangements with Sonic Healthcare and Helius Pathology networks, supporting national test access and fulfilment.

In parallel, BCAL launched EarlyDetection.com.au, its telehealth service developed with Medmate, on 12 May 2026. The service provides an additional medically supported pathway for eligible patients to access BCAL's early detection tests. Dr Martin A. Devitt has been appointed Medical Director of the Centre for Early Detection, strengthening clinical governance as the Company expands access to its testing portfolio. The EarlyDetection platform has also been registered in New Zealand, the United Kingdom, the United States, India and other international markets, supporting BCAL's longer-term strategy to develop scalable access pathways for its early detection portfolio beyond Australia.

BCAL's available and planned early detection portfolio includes BREASTESTplus™, Avantect® Pancreatic, and Avantect® Ovarian. The new Avantect® multi-cancer early detection test is expected to be available in the Australian market in June 2026.

The Company is also establishing a Sydney CBD high-risk early detection clinic to support patients who may benefit from medical consultation, risk assessment and access to blood-based testing.

BCAL Executive Chair Jayne Shaw said, *"This is an important commercialisation milestone for BCAL as we scale distribution of our early detection tests through existing healthcare workflows. Our GP, specialist, telehealth and clinic channels are designed to make it easier for clinicians and patients to access BCAL's test portfolio, supporting broader national adoption of blood-based early cancer detection."*

"This infrastructure is particularly important as we expand access to tests addressing significant market opportunities, including pancreatic cancer testing, where BCAL has previously estimated the Australian addressable market alone is greater than A\$250 million per annum."

This announcement has been approved for release by the Board of BCAL.

ENDS

For further information:

Jayne Shaw

Executive Chair

Jshaw@bcaldiagnostics.com

About BCAL Diagnostics

BCAL is an Australian health care company engaged in early cancer detection. BCAL launched its first test BREASTESTplus™ as a 'rule-out' test designed to be used in the clinical evaluation of breast disease for women with dense breasts. BREASTESTplus™ is a simple, non-invasive blood test used in conjunction with mammography to improve screening and diagnostic outcomes for breast health in women.

BCAL holds exclusive license with ClearNote Health Inc., a US-based precision diagnostics company, for the sale and distribution of Avantect Pancreatic, Avantect Ovarian and Avantect multi-cancer blood tests in Australia and New Zealand.

For more information: <https://www.bcaldiagnostics.com/> or contact info@bcaldiagnostics.com.